三個皮匠報告
政策庫
new
付費
搜索

Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比-行業數據

Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比
4）安全性：總體安全性與口服司美格魯肽 似，以胃腸道不良反應為主，但停藥率明顯更高。最常見的不良事件是惡心、腹 和嘔吐；因 TEAE而停止研究藥物的參與者比例在 Danuglipron組中呈劑量反應（3%-34%），安慰劑組為 8%。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?398KB 圖片尺寸：2303*1028
同報告圖片
 / 36
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第1頁
fCBNZWFzdXJlbWVudCB8IFBsYWNlYm8gKG49NjYpIHwgRGFuZ2xpcGxvbiAobj00MTEpIHwgTm8uIG9mIFRFQUVzIHwgU2VyaW91cyBURUFFIHwgU2V2ZXJlIFRFQUUgfCBEaXNjb250aW51ZWQgc3R1ZHkgbWVkaWNhdGlvbiBiZWNhdXNlIG9mIFRFQUUgfCBEaXNjb250aW51ZWQgc3R1ZHkgbWVkaWNhdGlvbiBiZWNhdXNlIG9mIFRFQUUgYnV0IGNvbnRpbnVlZCBzdHVkeSB8IERpc2NvbnRpbnVlZCBzdHVkeSBiZWNhdXNlIG9mIFRFQUUgfCBQYXJ0aWNpcGFudHMgd2l0aCBnYXN0cm9pbnRlc3RpbmFsIGRpc29yZGVyIFRFQUUgfCBQYXJ0aWNpcGFudHMgd2l0aCBURUFFIChhbGwgcHJlZmVycmVkIHRlcm1zIHdpdGgg4omlNSUgaW4gYW55IHRyZWF0bWVudCBncm91cCkgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgTmF1c2VhIHwgMiAoMykgfCA1ICg3KSB8IDUgKDcpIHwgMTEgKDE1KSB8IDIyICgzMykgfCA2OCAoMTcpIHwgIHwgIHwgIHwgIHwKfCBEaWFycmhlYSB8IDIgKDMpIHwgMyAoNCkgfCA0ICg2KSB8IDggKDExKSB8IDEyICgxOCkgfCAzNiAoOSkgfCAgfCAgfCAgfCAgfAp8IFZvbWl0aW5nIHwgMCB8IDAgfCAxICgxKSB8IDUgKDcpIHwgMTEgKDE2KSB8IDE4ICgyNSkgfCAzNSAoOSkgfCAgfCAgfCAgfAp8IEhlYWRhY2hlIHwgNCAoNikgfCA0ICg2KSB8IDEgKDEpIHwgNSAoNykgfCAyICgzKSB8IDcgKDEwKSB8IDIzICg2KSB8ICB8ICB8ICB8CnwgRHlzcGVwc2lhIHwgMCB8IDQgKDYpIHwgMyAoNCkgfCAyICgzKSB8IDkgKDEzKSB8IDIgKDMpIHwgMjAgKDUpIHwgIHwgIHwgIHwKfCBIeXBvZ2x5Y2VtaWEgfCAwIHwgMSAoMSkgfCAxICgxKSB8IDQgKDYpIHwgNiAoOSkgfCAzICg0KSB8IDE1ICg0KSB8ICB8ICB8ICB8CnwgRGl6emluZXNzIHwgMSAoMikgfCAxICgxKSB8IDQgKDYpIHwgMyAoNCkgfCAxICgxKSB8IDUgKDcpIHwgMTUgKDQpIHwgIHwgIHwgIHwKfCBHYXN0cm9lc29waGFnZWFsIHJlZmx1eCBkaXNlYXNlIHwgMCB8IDEgKDEpIHwgMiAoMykgfCAyICgzKSB8IDQgKDYpIHwgNSAoNykgfCAxNCAoMykgfCAgfCAgfCAgfAp8IFNBUlMtQ29WLTIgdGVzdCByZXN1bHQgcG9zaXRpdmUgfCAyICgzKSB8IDQgKDYpIHwgMyAoNCkgfCAzICg0KSB8IDEgKDEpIHwgMSAoMSkgfCAxNCAoMykgfCAgfCAgfCAgfAp8IEh5cGVyZ2x5Y2VtaWEgfCA2ICg5KSB8IDIgKDMpIHwgMSAoMSkgfCAwIHwgNCAoNikgfCAwIHwgMTMgKDMpIHwgIHwgIHwgIHwKfCBBYmRvbWluYWwgZGlzdGVuc2lvbiB8IDEgKDIpIHwgMCB8IDEgKDEpIHwgNCAoNikgfCAzICg0KSB8IDIgKDMpIHwgMTEgKDMpIHwgIHwgIHwgIHwKfCBEZWNyZWFzZWQgYXBwZXRpdGUgfCAwIHwgMiAoMykgfCAwIHwgMiAoMykgfCAxICgxKSB8IDUgKDcpIHwgMTAgKDIpIHwgIHwgIHwgIHwKfCBVcmluYXJ5IHRyYWN0IGluZmVjdGlvbiB8IDAgfCAxICgxKSB8IDAgfCA1ICg3KSB8IDMgKDQpIHwgMSAoMSkgfCAxMCAoMikgfCAgfCAgfCAgfAp8IEh5cGVydGVuc2lvbiB8IDAgfCAxICgxKSB8IDMgKDQpIHwgMSAoMSkgfCA0ICg2KSB8IDEgKDEpIHwgMTAgKDIpIHwgIHwgIHwgIHwKCui1hOaWmeadpea6kO+8mkpBTUEgTmV0d29yayBPcGVuLCBUaGUgTGFuY2V0LCDplb/msZ/or4HliLjnoJTnqbbmiYA=
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第2頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第3頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第4頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第5頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第6頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第7頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第8頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第9頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第10頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第11頁
fCBBIHwgQiB8IEMgfCBEIHwgROKCgSB8IETigoIgfCBE4oKDIHwgUuKChCB8IFLigoUgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgLSB8IC0gfCAtIHwgLSB8IC0gfCAtIHwgLSB8IC0gfCAtIHwKCui1hOaWmeadpea6kO+8muS4k+WIqSBXTzIwMjIyMzU3MTdBMe+8jOmVv+axn+ivgeWIuOeglOeptuaJgA==
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第12頁
fCDpobnnm64gfCDmj4/ov7AgfAp8IC0tLSB8IC0tLSB8CnwgU05BQyB8IFNvZGl1bSBOLSg4LSgyLWh5ZHJveHliZW56b3lsKSBBbWlubykgQ2FwcnlsYXRlIHwKfCDkvZznlKggfCDkuK3lkozog4PmtrJwSOWAvO+8jOS/neaKpHNlbWFnbHV0aWRl5YWN5Y+X6JuL55m95rC06Kej6ZmN6KejIHwKfCDphY3lkIggfCDkuI5zZW1hZ2x1dGlkZeWFseWQjOmFjeWItu+8jOS/g+i/m+WFtui3qOiDg+m7j+iGnOeahOWQuOaUtiB8CgrotYTmlpnmnaXmupA6IEludGVybmF0aW9uYWwgSm91cm5hbCBvZiBNb2xlY3VsYXIgU2NpZW5jZXMsIOmVv+axn+ivgeWIuOeglOeptuaJgA==
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第13頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第14頁
fCBBIHwgQiB8IEMgfCBSMSB8IFIyIHwgUjMgfCBMMSB8IEwyIHwgUTEgfCBRMiB8IFEzIHwgUTQgfCBRNSB8CnwtLS18LS0tfC0tLXwtLS0tfC0tLS18LS0tLXwtLS0tfC0tLS18LS0tLXwtLS0tfC0tLS18LS0tLXwtLS0tfAp8IE4gfCBOIHwgTiB8IFIxIHwgUjIgfCBSMyB8IEwxIHwgTDIgfCBRMSB8IFEyIHwgUTMgfCBRNCB8IFE1IHwKCui1hOaWmeadpea6kO+8muS4k+WIqSBXTzIwMjExNTU4NDFBMe+8jOmVv+axn+ivgeWIuOeglOeptuaJgA==
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第15頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第16頁
fCDnu5PmnoQgfCDljJblkIjniakgfAp8IC0tLSB8IC0tLSB8CnwgRU9DNTAwNCB8IE9yZm9yZ2xpcHJvbiB8Cnwg546v5bex6YWuIHwg546v5bex6YWuIHwKfCDmsJ/ljp/lrZAgfCDmsJ/ljp/lrZAgfAp8IOeOr+W3seeDtyB8IOeOr+W3seeDtyB8Cnwg5rCu5Y6f5a2QIHwg5rCu5Y6f5a2QIHwKCui1hOaWmeadpea6kO+8mkV4ZW5tZW4g572R56uZ77yM6ZW/5rGf6K+B5Yi456CU56m25omA
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第17頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第18頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第19頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第20頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第21頁
fCBSwrkgfCBSwrIgfCBSwrMgfCBS4oG0IHwgUuKBtSB8IFLigbYgfCBS4oG3IHwgUuKBuCB8IFLigbkgfCBSwrnigbAgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgTiB8IE4gfCBOIHwgTiB8IE4gfCBOIHwgTiB8IE4gfCBOIHwgTiB8CgrotYTmlpnmnaXmupDvvJrkuJPliKkgQ04xMTM4MTY5NDhC77yM6ZW/5rGf6K+B5Yi456CU56m25omA
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第22頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第23頁
fCDmlrnms5UgICAgICAgICB8IOeUn+eJqeWIqeeUqOW6piB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg55qu5LiL5rOo5bCE5Y+4576OIHwgODklICAgICAgICB8Cnwg5Y+j5pyN5Y+4576OICAgICB8IDAuNC0xJSAgICAgfAoK6LWE5paZ5p2l5rqQ77yaUnliZWxzdXMg6K+05piO5Lmm77yMUGhpcmRhIOWumOe9ke+8jOmVv+axn+ivgeWIuOeglOeptuaJgA==
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第24頁
fCBQZXB0aWRlIGJpbmRpbmcgfCBHIHByb3RlaW4gY291cGxpbmcsIG51Y2xlb3RpZGUgcmVtb3ZhbCB8IEdMUC0xIHwgRUNEIHwgVE1EIHwgT3BlbiwgYWN0aXZlIHN0YXRlIHwgRy1wcm90ZWluIHwKfC0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tfC0tLS0tfC0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLXwKfCBSICAgICAgICAgICAgICAgfCDOsTxzdWI+UmFzPC9zdWI+LCDOss6zLCDOsTxzdWI+QUg8L3N1Yj4gICB8ICAgICAgIHwgICAgIHwgICAgIHwgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICB8CnwgUjxzdXA+Kzwvc3VwPiAgfCDOsTxzdWI+UmFzPC9zdWI+LCDOss6zLCDOsTxzdWI+QUg8L3N1Yj4gICB8ICAgICAgIHwgICAgIHwgICAgIHwgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICB8CgrotYTmlpnmnaXmupA6IE5hdCBDb21tdW48c3VwPjI8L3N1cD4sIE5hdHVyZTxzdXA+Mzwvc3VwPiwg6ZW/5rGf6K+B5Yi456CU56m25omA
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第25頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第26頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第27頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第28頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第29頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第30頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第31頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第32頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第33頁
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
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第34頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第35頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第36頁
Danuglipron針對糖尿病患者的IIb期臨床、以及每日一次口服50mg司美格魯肽安全性數據對比_第37頁
所屬報告： 醫療保健行業GLP~1R小分子激動劑：輝瑞與禮來領銜Follow如火如荼-240821（27頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站